Loading
A phase 1/2 trial of Cevostamab, Lenalidomide, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma is a phase 1/2 interventional study registered as NCT05583617 by Hoffmann-La Roche, with 200 participants planned, started 2023-11-14 and due to reach its primary completion in 2028-07-31. Interventions recorded: Cevostamab, Lenalidomide, Tocilizumab, Iberdomide, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cevostamab, Tocilizumab, Roche / Genentech, Multiple myeloma.
Shares Cevostamab, Roche / Genentech, Multiple myeloma.
Shares Iberdomide, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Iberdomide, Lenalidomide, Multiple myeloma.
Shares Tocilizumab, Lenalidomide, Roche / Genentech.
Shares Cevostamab, Multiple myeloma.
Shares Iberdomide, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/